Skip to main content
. Author manuscript; available in PMC: 2019 Jun 3.
Published in final edited form as: J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218821963. doi: 10.1177/2325958218821963

Figure 1.

Figure 1.

Prevalence of renal impairment*, overall, and by tenofovir exposure over 144 weeks of antiretroviral therapy. * denotes patient met 1 or more of the defined criteria for renal impairment based on eGFR <60 mL/min/1.73 m2 or a doubling of serum creatinine from baseline. TDF indicates tenofovir disoproxil fumarate.